Mendelian randomization analysis identified 19 potential therapeutic targets for hypertrophic cardiomyopathy (HCM) and 13 for dilated cardiomyopathy (DCM) by examining genetic variants affecting protein levels and gene expression. The study used cardiac magnetic resonance imaging data to map how these targets influence disease risk through specific heart structural changes. For HCM, protective effects of the ALPK3 protein worked by reducing heart wall thickness, while for DCM, proteins PDLIM5, HSPA4, and FBXO32 influenced disease risk through changes in aortic dimensions. This approach represents a significant advance in precision cardiology, offering a systematic framework to identify drug targets before expensive clinical trials begin. The integration of genetics with detailed heart imaging provides mechanistic insights that could guide treatment development for conditions affecting millions globally. However, this preprint awaits peer review, and the findings require validation in diverse populations and clinical studies. The work is particularly valuable given the limited therapeutic options for these inherited heart muscle diseases, which can cause sudden cardiac death in young adults. These genetic insights could accelerate development of targeted therapies.